Compare ASE Technology Holding Co Ltd (ASX) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASE Technology Holding Co Ltd vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? ASE Technology Holding Co Ltd trades at $39.11 (market cap $85.75B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B). The key difference: ASE Technology Holding Co Ltd is far larger — about 9.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and ASE Technology Holding Co Ltd pays a 1.08% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| ASX | BIO | |
|---|---|---|
Market Cap | $85.75B | $9.43B |
Sector | Technology | Health |
52-Week High | $45.12 | $356.25 |
52-Week Low | $9.63 | $241.71 |
Enterprise Value | $90.15B | $9.18B |
Dividend Yield | 1.08% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
